Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 130

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 18
Chunk 130
---
Contributions of equity/                                                                             -                     -                        -                       -                                  -    
Shares to be issued                                                                                                                                                                                                 
Issuance of shares in connection with exercise of options, net of costs   10(b) &amp; 11(b)          6,428,732             23,540                   (23,540     )           -                                  -    
Transaction costs from issuance of shares                                                            -                     (2,774,168    )          -                       -                         (2,774,168   )
Expired options                                                                                      -                     -                        (326,544    )           326,544                            -    
Forfeited options                                                                                    -                     -                        (93,735     )           93,735                             -    
                                                                                                     3,882,255,368         39,796,477               536,101                 420,279                   40,752,857    
Net loss                                                                                             -                     -                        -                       (12,147,828    )         (12,147,828   )
Total comprehensive loss for the year                                                                -                     -                        -                       (12,147,828    )         (12,147,828   )
Balance, June 30, 2025                                                                               9,127,370,686         262,949,462              5,342,304               (225,888,680   )          42,403,086    

The accompanying notes are an integral part of the consolidated financial statements.

F-7

ALTERITY THERAPEUTICS LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – in Australian dollars (unless otherwise noted)

1. BACKGROUND AND SUMMARY OF MATERIAL ACCOUNTING POLICIES
 
Background
 
Alterity Therapeutics Limited and its controlled subsidiaries, Alterity Therapeutics Inc. and Alterity Therapeutics UK Limited (referred to collectively as “Alterity” or the “Group”), is a development stage enterprise engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. Alterity Therapeutics Limited, the parent entity, was incorporated on November 11, 1997 in Melbourne, Australia and the UK and U.S. subsidiaries were incorporated in August 2004.   Financial Reporting Framework
   The financial report of Alterity Therapeutics Limited for the year ended June 30, 2025 was authorized for issue on August 29, 2025